What to look forward to in GaBI Journal, 2018, Issue 2
Potential changes to the FDA approach to biosimilars have a global impact
Protein heterogeneity and the immunogenicity of biotherapeutics
Regulation of copy biologicals in China
Biosimilar regulation and approval in Jordan
Quality assessment of biosimilars in Colombia – reducing knowledge gaps
Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance
A call for coherence in EU legislation to promote generics
Source URL: https://gabi-journal.net/2018-2-gabi-journal-table-of-contents.html
Copyright ©2024 GaBI Journal unless otherwise noted.